Seminar “Multiple Myeloma 2016—State of The Art”

Klipi teostus: UTTV 09.09.2016 4149 vaatamist Medicina Arstiteadus

Multiple myeloma (MM) is a neoplastic disease of bone marrow and accounts for approximately 13% of all hematologic cancers. In Estonia the survival of MM is only 30 months whereas in the US it is considerably higher. This difference is mainly explained by different access to anti-myeloma agents in the US and Europe. On 9 September, experts of the subject from Estonia, the US and elsewhere will meet at the University of Tartu to discuss the latest developments of the disease and increase research cooperation with the US to improve the survival of MM patients in Estonia.

Lisainfo veebis: